Searchable abstracts of presentations at key conferences in endocrinology

ea0077op5.4 | Bone and Calcium | SFEBES2021

Normocalcaemic hyperparathyroidism: Impact of assay and reference range differences on the diagnosis

Fenn Jonathan , Kalaria Tejas , Sanders Anna , Ford Clare , Gama Rousseau

Approximately 70% of clinical laboratories in the United Kingdom use assays from Abbott Laboratories and Roche Diagnostics. We carried out a cross-sectional study between two neighbouring hospital laboratories in our regional pathology network, comparing the potential impact of Abbott and Roche PTH and calcium assays in the diagnosis of normocalcaemic hyperparathyroidism. Over 4 months, forty-one vitamin D replete (>50 nmol/l) normocalcaemic hyperparathyroidism patients (3...

ea0074ncc48 | Highlighted Cases | SFENCC2021

The pragmatic use of corticosteroids in the diagnosis and treatment of non-PTH driven hypercalcaemia

Yousif Yasear Zainab Akram , Ijaz Nadia , Gittoes Neil , Sanders Anna , Pang Terence

A 65-year-old gentleman was referred by his GP because of acute kidney injury and hypercalcaemia, which was associated with low levels of parathyroid hormone. He had been fit and well and was on no regular medications. Whilst his hypercalcaemia was partly correctible with saline rehydration, cautious use of bisphosphonates and cinacalcet were not effective in preventing rebound, and his nephropathy persisted. Curiously, he had longstanding low plasma alkaline phosphatase, but had normal denti...